We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Lilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement PR Newswire INDIANAPOLIS, Jan. 23, 2025 INDIANAPOLIS, Jan. 23, 2025...
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease PR Newswire INDIANAPOLIS, Jan. 15, 2025 In the pivotal...
Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance PR Newswire INDIANAPOLIS, Jan. 14, 2025 2024 revenue is expected to be approximately $45.0 billion for the full...
Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program PR Newswire INDIANAPOLIS and BOSTON, Mass., Jan. 13, 2025 The acquisition will expand Lilly's oncology pipeline...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions